Australian Clinical Labs Ltd - Asset Resilience Ratio

Latest as of December 2025: 4.11%

Australian Clinical Labs Ltd (ACL) has an Asset Resilience Ratio of 4.11% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Australian Clinical Labs Ltd (ACL) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$23.14 Million
≈ $16.37 Million USD Cash + Short-term Investments

Total Assets

AU$562.50 Million
≈ $398.00 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Australian Clinical Labs Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Australian Clinical Labs Ltd assets under control.

Liquid Assets Composition Over Time

This chart breaks down Australian Clinical Labs Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Australian Clinical Labs Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$22.43 Million 3.99%
Short-term Investments AU$703.00K 0.12%
Total Liquid Assets AU$23.14 Million 4.11%

Asset Resilience Insights

  • Limited Liquidity: Australian Clinical Labs Ltd maintains only 4.11% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Australian Clinical Labs Ltd Industry Peers by Asset Resilience Ratio

Compare Australian Clinical Labs Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Green Cross Lab Cell Corporation
KQ:144510
Diagnostics & Research 0.18%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
Scope Fluidics SA
WAR:SCP
Diagnostics & Research 16.51%
Eurofins-Cerep SA
PA:ALECR
Diagnostics & Research 13.42%
Check-Cap Ltd
F:7CC
Diagnostics & Research 2.90%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Cryosite Ltd
AU:CTE
Diagnostics & Research 5.65%

Annual Asset Resilience Ratio for Australian Clinical Labs Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Australian Clinical Labs Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 3.85% AU$22.12 Million
≈ $15.65 Million
AU$574.84 Million
≈ $406.73 Million
0.00pp
2024-12-31 3.85% AU$22.12 Million
≈ $15.65 Million
AU$574.84 Million
≈ $406.73 Million
-0.68pp
2024-06-30 4.53% AU$26.84 Million
≈ $18.99 Million
AU$593.06 Million
≈ $419.63 Million
0.00pp
2023-12-31 4.53% AU$26.84 Million
≈ $18.99 Million
AU$593.06 Million
≈ $419.63 Million
+0.97pp
2023-06-30 3.56% AU$20.59 Million
≈ $14.57 Million
AU$578.91 Million
≈ $409.62 Million
0.00pp
2022-12-31 3.56% AU$20.59 Million
≈ $14.57 Million
AU$578.91 Million
≈ $409.62 Million
+3.38pp
2022-06-30 0.18% AU$1.13 Million
≈ $802.38K
AU$628.04 Million
≈ $444.38 Million
-4.20pp
2021-12-31 4.38% AU$27.51 Million
≈ $19.46 Million
AU$628.04 Million
≈ $444.38 Million
+4.16pp
2021-06-30 0.22% AU$1.05 Million
≈ $742.23K
AU$474.70 Million
≈ $335.88 Million
-7.42pp
2020-12-31 7.64% AU$36.28 Million
≈ $25.67 Million
AU$474.70 Million
≈ $335.88 Million
+7.52pp
2020-06-30 0.12% AU$435.00K
≈ $307.79K
AU$366.05 Million
≈ $259.01 Million
-9.52pp
2019-12-31 9.64% AU$35.28 Million
≈ $24.97 Million
AU$366.05 Million
≈ $259.01 Million
+8.99pp
2019-06-30 0.65% AU$1.00 Million
≈ $708.27K
AU$153.61 Million
≈ $108.69 Million
-2.69pp
2018-12-31 3.34% AU$5.13 Million
≈ $3.63 Million
AU$153.61 Million
≈ $108.69 Million
+0.89pp
2018-06-30 2.45% AU$2.91 Million
≈ $2.06 Million
AU$119.06 Million
≈ $84.24 Million
-5.77pp
2017-12-31 8.22% AU$9.78 Million
≈ $6.92 Million
AU$119.06 Million
≈ $84.24 Million
+7.97pp
2017-06-30 0.25% AU$301.00K
≈ $212.98K
AU$120.89 Million
≈ $85.54 Million
-5.82pp
2016-12-31 6.07% AU$7.34 Million
≈ $5.19 Million
AU$120.89 Million
≈ $85.54 Million
--
pp = percentage points

About Australian Clinical Labs Ltd

AU:ACL Australia Diagnostics & Research
Market Cap
$374.47 Million
AU$529.24 Million AUD
Market Cap Rank
#14014 Global
#370 in Australia
Share Price
AU$2.82
Change (1 day)
+3.30%
52-Week Range
AU$1.84 - AU$2.99
All Time High
AU$5.09
About

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veter… Read more